Recipharm AB and Astimex Pharma AB have entered a collaboration agreement for the development and manufacture of a pharmaceutical product. Recipharm will provide formulation development from its site in Solna, near Stockholm. Astimex will have the opportunity to choose Recipharm as the future manufacturer for the product. Astimex is also considering Recipharm for the manufacture and development of other contractual projects.
Maria Lundberg, general manager of Recipharm, said, “I am convinced that this is the start of a long-term collaboration that will prove beneficial for both companies and we are pleased that Astimex Pharma have chosen to utilize the expertise and flexible development capabilities that our staff and facilities are able to provide.”
Asa Lintzen, general manager of Astimex Pharma, said, “We are delighted to be working closely with Recipharm on this specific manufacturing and development project. Indeed, it is Recipharm’s recognized partnering approach, combined with its advanced and adaptable capabilities, including its offering at the Solna facility that attracted us in the first place. Moreover, we were looking for a CDMO that we could build a long term relationship with and consequently we are already exploring the scope for working with Recipharm on other projects.”